Cargando…
Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion
OBJECTIVE: The aim of this study was to assess the detection ability of (68)Ga-DOTATATE in pulmonary versus extrapulmonary tumors with ectopic adrenocorticotropic hormone secretion (EAS). METHODS: Images of (68)Ga-DOTATATE PET/CT from 74 patients with suspected EAS were retrospectively reviewed. EAS...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348477/ https://www.ncbi.nlm.nih.gov/pubmed/37456258 http://dx.doi.org/10.3389/fonc.2023.1204963 |
_version_ | 1785073673207545856 |
---|---|
author | Wang, Junhu Luan, Zhonghua Li, Ting Guan, Xiaodong |
author_facet | Wang, Junhu Luan, Zhonghua Li, Ting Guan, Xiaodong |
author_sort | Wang, Junhu |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to assess the detection ability of (68)Ga-DOTATATE in pulmonary versus extrapulmonary tumors with ectopic adrenocorticotropic hormone secretion (EAS). METHODS: Images of (68)Ga-DOTATATE PET/CT from 74 patients with suspected EAS were retrospectively reviewed. EAS tumors were confirmed in 39 patients through surgical resection or biopsy. Image findings were compared with the histopathological results. RESULTS: EAS tumors were pathologically confirmed via surgery or biopsy in 39 patients. Among those 39 patients, 25 were with pulmonary neuroendocrine tumors (NETs), and the remaining 14 were with extrapulmonary NETs. (68)Ga-DOTATATE PET/CT correctly identified the tumor in 26 patients, rendering an overall detection rate of 66.7%. On a site-based analysis, (68)Ga-DOTATATE PET/CT correctly identified the EAS tumor in 13 of 25 patients with pulmonary NETs, yielding a detection rate of 52%; for the 14 patients with extrapulmonary NETs, (68)Ga-DOTATATE PET/CT correctly identified the EAS tumor in 13, yielding a detection rate of 92.9%. The detection rate of (68)Ga-DOTATATE was significantly higher in extrapulmonary NETs than in pulmonary NETs (92.9%% vs. 52%, P = 0.013). For the 13 patients with positive pulmonary NETs, the tumor SUVmax ranged from 1.1 to 7.4 with an average SUVmax of 3.1 ± 2.1. For the 13 patients with positive extrapulmonary NETs, the tumor SUVmax ranged from 2.7 to 21.8 with an average SUVmax of 9.9 ± 6.3. The tumor SUVmax was significantly higher in extrapulmonary tumors than pulmonary tumors (P = 0.015). The tumor size was smaller in pulmonary tumors than in extrapulmonary tumors, while the difference was not significant (P = 0.516). CONCLUSION: (68)Ga-DOTATATE showed site-specific difference in detecting tumors with EAS secretion. Specifically, (68)Ga-DOTATATE performed better in the extrapulmonary EAS tumors than in pulmonary ones with both higher detection rate and uptake. Combination of anatomic imaging techniques are necessary for the correct diagnosis of pulmonary EAS tumors. |
format | Online Article Text |
id | pubmed-10348477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103484772023-07-15 Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion Wang, Junhu Luan, Zhonghua Li, Ting Guan, Xiaodong Front Oncol Oncology OBJECTIVE: The aim of this study was to assess the detection ability of (68)Ga-DOTATATE in pulmonary versus extrapulmonary tumors with ectopic adrenocorticotropic hormone secretion (EAS). METHODS: Images of (68)Ga-DOTATATE PET/CT from 74 patients with suspected EAS were retrospectively reviewed. EAS tumors were confirmed in 39 patients through surgical resection or biopsy. Image findings were compared with the histopathological results. RESULTS: EAS tumors were pathologically confirmed via surgery or biopsy in 39 patients. Among those 39 patients, 25 were with pulmonary neuroendocrine tumors (NETs), and the remaining 14 were with extrapulmonary NETs. (68)Ga-DOTATATE PET/CT correctly identified the tumor in 26 patients, rendering an overall detection rate of 66.7%. On a site-based analysis, (68)Ga-DOTATATE PET/CT correctly identified the EAS tumor in 13 of 25 patients with pulmonary NETs, yielding a detection rate of 52%; for the 14 patients with extrapulmonary NETs, (68)Ga-DOTATATE PET/CT correctly identified the EAS tumor in 13, yielding a detection rate of 92.9%. The detection rate of (68)Ga-DOTATATE was significantly higher in extrapulmonary NETs than in pulmonary NETs (92.9%% vs. 52%, P = 0.013). For the 13 patients with positive pulmonary NETs, the tumor SUVmax ranged from 1.1 to 7.4 with an average SUVmax of 3.1 ± 2.1. For the 13 patients with positive extrapulmonary NETs, the tumor SUVmax ranged from 2.7 to 21.8 with an average SUVmax of 9.9 ± 6.3. The tumor SUVmax was significantly higher in extrapulmonary tumors than pulmonary tumors (P = 0.015). The tumor size was smaller in pulmonary tumors than in extrapulmonary tumors, while the difference was not significant (P = 0.516). CONCLUSION: (68)Ga-DOTATATE showed site-specific difference in detecting tumors with EAS secretion. Specifically, (68)Ga-DOTATATE performed better in the extrapulmonary EAS tumors than in pulmonary ones with both higher detection rate and uptake. Combination of anatomic imaging techniques are necessary for the correct diagnosis of pulmonary EAS tumors. Frontiers Media S.A. 2023-06-30 /pmc/articles/PMC10348477/ /pubmed/37456258 http://dx.doi.org/10.3389/fonc.2023.1204963 Text en Copyright © 2023 Wang, Luan, Li and Guan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wang, Junhu Luan, Zhonghua Li, Ting Guan, Xiaodong Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion |
title | Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion |
title_full | Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion |
title_fullStr | Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion |
title_full_unstemmed | Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion |
title_short | Site-specific performance of (68)Ga-DOTATATE PET/CT in detecting tumors with ectopic adrenocorticotropic hormone secretion |
title_sort | site-specific performance of (68)ga-dotatate pet/ct in detecting tumors with ectopic adrenocorticotropic hormone secretion |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348477/ https://www.ncbi.nlm.nih.gov/pubmed/37456258 http://dx.doi.org/10.3389/fonc.2023.1204963 |
work_keys_str_mv | AT wangjunhu sitespecificperformanceof68gadotatatepetctindetectingtumorswithectopicadrenocorticotropichormonesecretion AT luanzhonghua sitespecificperformanceof68gadotatatepetctindetectingtumorswithectopicadrenocorticotropichormonesecretion AT liting sitespecificperformanceof68gadotatatepetctindetectingtumorswithectopicadrenocorticotropichormonesecretion AT guanxiaodong sitespecificperformanceof68gadotatatepetctindetectingtumorswithectopicadrenocorticotropichormonesecretion |